Keywords: Novo Nordiskm Levemir, Young children, USA, FDA, Type 1 diabetes, Prizer, Tefamidis, Vyndaqel, Briefing documents, Polyneuropathy

FDA expands Levemir use to young children; negative on tafamidis

Article | 23 May 2012

Print This

Denmark-based global insulin giant Novo Nordisk (NOV: N) says that the US Food and Drug Administration has approved Levemir (insulin ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in